Scott, L., Fraser, J. and Cassidy, J. (2003) Emerging drugs in colorectal cancer. Expert Opinion in Emerging Drugs, 8(1), pp. 193-202. (doi: 10.1517/14728214.8.1.193)
Full text not currently available from Enlighten.
Abstract
A raft of novel agents with different modes of action is finally challenging the position of 5-fluorouracil (5-FU) as the gold standard treatment for colorectal cancer. Oral fluoropyrimidines, topoisomerase I inhibitors and new generation platinum compounds are all currently being investigated. There is also increasing interest in the development and use of biological therapies, which may allow treatments to become tailored to individual patients and cause less toxicity than conventional cytotoxics. It is hoped that with the development of these new drugs, the response rates and survival for patients with colorectal cancer will improve from the poor prognosis that many face at present.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Cassidy, Professor James |
| Authors: | Scott, L., Fraser, J., and Cassidy, J. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Expert Opinion in Emerging Drugs |
| ISSN: | 1472-8214 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details